This study evaluated renal, cardiovascular, and systemic outcomes associated with GLP-1 RA therapy in adults with type 2 diabetes and body mass index (BMI) ≤ 30 kg/m2.<h4>Materials and methods</h4>We conducted a real-world, target trial emulation, retrospective cohort study using the TriNetX US Collaborative Network. Here, GLP1R is linked to type 2 diabetes mellitus.